Jefferies Financial Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $432.00

United Therapeutics (NASDAQ:UTHR) had its target price hoisted by equities research analysts at Jefferies Financial Group from $315.00 to $432.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Jefferies Financial Group’s price objective would indicate a potential upside of 20.71% from the stock’s current price.

Several other equities analysts also recently commented on UTHR. Wells Fargo & Company upped their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. UBS Group increased their price target on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, Oppenheimer lifted their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $357.17.

United Therapeutics Trading Up 0.6 %

Shares of UTHR stock opened at $357.87 on Monday. The company has a market cap of $15.87 billion, a PE ratio of 16.92, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The stock’s 50 day simple moving average is $340.35 and its two-hundred day simple moving average is $293.69. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same quarter in the prior year, the business earned $5.24 earnings per share. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Research analysts predict that United Therapeutics will post 24.86 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $41,658.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $41,658.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $569,362.50. The disclosure for this sale can be found here. Insiders have sold a total of 114,852 shares of company stock valued at $38,079,259 over the last ninety days. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $3,471,000. Cetera Investment Advisers lifted its stake in shares of United Therapeutics by 8.7% during the second quarter. Cetera Investment Advisers now owns 6,167 shares of the biotechnology company’s stock worth $1,964,000 after buying an additional 493 shares during the period. Brandes Investment Partners LP grew its holdings in shares of United Therapeutics by 4.9% during the second quarter. Brandes Investment Partners LP now owns 19,916 shares of the biotechnology company’s stock valued at $6,332,000 after buying an additional 926 shares during the last quarter. B. Riley Wealth Advisors Inc. grew its holdings in shares of United Therapeutics by 10.2% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,067 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 99 shares during the last quarter. Finally, Capital Impact Advisors LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $954,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.